Glucotrack (GCTK) Net Equity Issued and Repurchased (2011 - 2020)

Glucotrack's Net Equity Issued and Repurchased history runs 6 years deep, the most recent figure standing at $13.0 million for Q1 2020.

• Quarterly Net Equity Issued and Repurchased rose 1634.27% year-over-year to $13.0 million in Q1 2020, while the trailing twelve-month figure through Dec 2020 was $13.0 million (up 202.22% YoY) and the FY2020 annual result came in at $13.0 million, up 212.34% from the prior year.
• Net Equity Issued and Repurchased was $13.0 million for Q1 2020 at Glucotrack, up from -$79.0 in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $13.0 million in Q1 2020 and bottomed at -$79.0 in Q4 2019.
• A 4-year average of $3.0 million and a median of $924398.0 in 2018 frame the typical range for Net Equity Issued and Repurchased.
• Annual changes were most pronounced in 2019 — Net Equity Issued and Repurchased sank 100.06% — and 2020, when it soared 1634.27%.
• Glucotrack's Net Equity Issued and Repurchased stood at $7.3 million in 2016, then sank by 98.09% to $139416.0 in 2018, then sank by 100.06% to -$79.0 in 2019, then jumped by 16467188.61% to $13.0 million in 2020.
• Business Quant data shows GCTK's Net Equity Issued and Repurchased at $13.0 million in Q1 2020, -$79.0 in Q4 2019, and $3.4 million in Q2 2019.